Increased expression and activation of CD30 induce apoptosis in human blood eosinophils

被引:27
作者
Berro, AI
Perry, GA
Agrawal, DK
机构
[1] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA
[2] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA
[3] Creighton Univ, Sch Med, Dept Internal Med, Omaha, NE 68178 USA
[4] Creighton Univ, Sch Med, Ctr Allergy Asthma & Immunol, Omaha, NE 68178 USA
关键词
D O I
10.4049/jimmunol.173.3.2174
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Eosinophils are one. of the major effector cells in asthma, and controlling the number and survival of eosinophils might attenuate the severity of asthma. This result could be achieved by inducing eosinophil apoptosis. Apoptosis allows the removal of cells without inducing an inflammatory response. Our knowledge of the factors involved, in regulating eosinophil apoptosis remains limited. CD30 molecule has been associated with T cell-negative selection and in TCR-mediated apoptosis. In this study we examined the expression and role of CD30 in apoptosis of human blood eosinophils. Percentage of apoptotic eosinophils was determined by annexin V-propidium iodide labeling, and CD30 expression was examined by flow cytometry. Spontaneous apoptosis was induced by serum deprivation, and survival was conferred by incubating cells with 10% FBS and IL-5. CD30 surface expression was up-regulated in eosinophils incubated for 24 h as compared with freshly isolated eosinophils, and both CD30 expression and eosinophil apoptosis increased in a time-dependent manner. We also measured CD30 mRNA expression by quantitative real-time RT-PCR and determined that CD30 transcripts increased in eosinophils undergoing apoptosis only under serum deprivation conditions. The agonistic CD30 Abs, Ber-H8 and HeFi-1, significantly enhanced eosinophil apoptosis. FBS and IL-5 failed to inhibit or suppress the CD30 agonistic-induced apoptosis. These data support the role of CD30 activation in eosinophil apoptosis. This research will help in furthering our understanding of eosinophil apoptosis and therefore might contribute to the development of better therapeutic modalities in the treatment and/or cure of allergic inflammation in bronchial asthma.
引用
收藏
页码:2174 / 2183
页数:10
相关论文
共 46 条
  • [1] Increased hypodense eosinophils after activation with PAF-acether and calcium ionophore in asthmatic subjects
    Agrawal, DK
    Sarmiento, EU
    Nabe, M
    Miyagawa, H
    Townley, RG
    [J]. JOURNAL OF ASTHMA, 1996, 33 (04) : 213 - 219
  • [2] Aizawa S, 1997, J BIOL CHEM, V272, P2042
  • [3] Morphological and biochemical characterization and analysis of apoptosis
    Allen, RT
    Hunter, WJ
    Agrawal, DK
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1997, 37 (04) : 215 - 228
  • [4] RETRACTED: Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation (Retracted article. See vol 94, pg 12732, 1997)
    Ansieau, S
    Scheffrahn, I
    Mosialos, G
    Brand, H
    Duyster, J
    Kaye, K
    Harada, J
    Dougall, B
    Hubinger, G
    Kieff, E
    Herrmann, F
    Leutz, A
    Gruss, HJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) : 14053 - 14058
  • [5] Barnes PJ, 1998, PHARMACOL REV, V50, P515
  • [6] Molecular and cellular mechanisms of allergic disease
    Broide, DH
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (02) : S65 - S71
  • [7] Advances in immunology - Asthma
    Busse, WW
    Lemanske, RF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) : 350 - 362
  • [8] Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
    Bustin, SA
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2000, 25 (02) : 169 - 193
  • [9] CD30 in normal and neoplastic cells
    Chiarle, R
    Podda, A
    Prolla, G
    Gong, J
    Thorbecke, GJ
    Inghirami, G
    [J]. CLINICAL IMMUNOLOGY, 1999, 90 (02) : 157 - 164
  • [10] Chiarle R, 1999, J IMMUNOL, V163, P194